We concluded that the role of Bcl-2 or Bcl-xL in modulation of prostate cancer cell sensitivity to combined cisplatin/LA-12 and TRAIL treatment may be cell type-specific, but not crucial in prostate cancer cell lines used within our study. This evidence concerns the gene BCL2 and prostate cancer.